Ride Health Raises Millions to Coordinate The Medical Transportation Ecosystem

Ride Health, providing smarter transportation for every patient need, announced they raised $6.2 million in a funding round led by Activate Venture Partners. The capital raise is joined by Newark Venture Partners, Anthro Ventures, BioAdvance, Leading Edge Ventures and Startup Health, according to a news release from Cision PR Newswire. Ride Health will use the funds in an initiative of ensuring every patient, everywhere, has access to the care and resources they need to ensure good health. Ride Health developed its real-time transportation coordination platform to overcome the significant challenges posed by traditional non-emergency medical transportation (NEMT) systems. Millions of Americans struggle with transportation barriers that impact their ability to access quality health care. Patients and caregivers have difficulty navigating limited transportation options; providers lose billions from no-shows and delayed discharges; care coordinators lack the necessary insights to make informed decisions on transportation options; and insurers pay tens of billions in avoidable healthcare expenses due to lapses in care transitions and access related to transportation, the release says.

Spotlight

Spotlight

Related News

Health Technology

Rudolf Riester GmbH Announces Global Market Launch of Telemedicine Solution, Showcases ri-sonic® E-Stethoscope + eMurmur® AI Integration

Rudolf Riester GmbH | January 29, 2024

Rudolf Riester GmbH, a global leader in medical technology, proudly announces the full market launch of its comprehensive Telemedicine offering. Already in active use across Europe, the Middle East, and Africa, the solution from the trusted Riester brand delivers industry-leading quality and versatility through integration of a broad range of medical devices to meet the needs of diverse user scenarios. "Since its founding 75 years ago, Riester has been a pioneer in providing accurate and efficient diagnostic devices for front-line healthcare. We have brought this passion and expertise to the creation of our telemedicine solution," said Dr. Georgiana Gasquères, Global Business Unit Director, Telemedicine at Riester. "Now we empower healthcare providers worldwide with the tools they need to deliver accurate diagnosis and exceptional care to every patient, everywhere, and to do it more sustainably." Riester is demonstrating its Telemedicine Case and Cart offerings at the Arab Health show in Dubai, 29 January – 1 February 2024, at booth SA.E30. Traveling nurses with South African healthcare innovator EQiGate are already evaluating dozens of patients every week with the Riester Telemedicine Case. "EQiGate selected the Riester Telemedicine solution for its high quality, comprehensiveness, and versatile, Windows-based compatibility with our portfolio of operating applications," stated Braam Kruger, CEO at EQiGate. "The Riester solution integrates seamlessly with our Hospital at Home concept, enabling us to bring the hospital to the patient, a healthcare paradigm shift that yields significant cost and time savings for both the healthcare system and the patient." At Arab Health, Riester is showcasing the integration of their industry-leading ri-sonic® E-stethoscope with the eMurmur® AI platform. Digital auscultation with ri-sonic and eMurmur AI enables the early detection and analysis of heart murmurs, informing better, more timely decisions about treatment pathways. To demonstrate their commitment to raising heart health awareness and improving quality of life through accurate and efficient diagnosis, Riester is offering complimentary advisory heart checks to all exhibition attendees at their booth at Arab Health, conducted by a professional cardiologist. "Our participation at Arab Health reaches beyond showcasing our technological advancements; it is about educating and engaging with the public – including Arab Health attendees – and healthcare professionals," said Irina Zhdanova, CEO of Riester. "By providing free advisory heart checks, we emphasise the significance of regular cardiac health assessments and demonstrate how innovative technology can be a pivotal tool in advancing diagnostic cardiac care to improve health outcomes. This is a perfect way to honor Riester’s 75-year heritage and act on our vision and mission." About Rudolf Riester GmbH Since its founding in Germany in 1948, Rudolf Riester GmbH has been a pioneering force in improving quality of life through accurate and efficient diagnosis on the front-line of healthcare. By developing and manufacturing high-quality, market-leading medical diagnostic products, Riester has earned a global reputation for quality, reliability, and innovation in the healthcare sector, with a presence in over 150 countries. Specializing in diagnostic devices, Riester's product portfolio includes telemedicine solutions as well as stethoscopes, blood pressure monitors, otoscopes, ophthalmoscopes, and other medical equipment. Riester is part of the Halma plc group of companies.

Read More

Health Technology

PureHealth Completes Acquisition of UK’s Largest Private Healthcare Group

PureHealth | January 16, 2024

PureHealth, the largest healthcare platform in the Middle East, has announced the successful completion of its strategic acquisition of Circle Health Group, UK’s largest independent operators of hospitals, marking a significant milestone in the company's global expansion strategy. The completion of this deal, which has achieved regulatory approvals in record time, signifies PureHealth’s exceptional operational capabilities and commitment to international growth. The completion of this transaction further strengthens PureHealth’s commitment to becoming a leading global player in healthcare. With a vision aligned with the UAE leadership to promote wellbeing and enhance healthcare services, PureHealth is dedicated to continuously improving patient experience and adopting the most advanced clinical practices. The company’s expansion into the UK healthcare market reflects its focus on advancing the science of longevity and unlocking time for humanity. Hamad Al Hammadi, Chairman of the Board of Directors of PureHealth, said: “We are pleased to complete the acquisition of Circle in record time. This remarkable achievement epitomises PureHealth's operational excellence and strategic adaptability in broadening its international impact. After investing in Ardent Health USA, this is PureHealth’s second international acquisition, and we look forward to building our portfolio internationally.” Farhan Malik, Founder and Managing Director of PureHealth, commented: “Completing the acquisition of Circle is a strategic leap forward for PureHealth. This acquisition is more than an expansion; it's a significant stride towards establishing PureHealth as a global healthcare platform. We are not just investing in the future of healthcare; we are shaping it to be more connected, innovative, and accessible on a global scale. This move aligns with our vision of pioneering a healthier future for all and underscores our commitment to elevating the global position of Abu Dhabi in the healthcare sector and revolutionising healthcare services globally. We look forward to fostering long term partnerships within the UK’s healthcare ecosystem.” Valued at c.USD 1.2 billion before debt, this acquisition marks a significant investment in the future of healthcare, positioning PureHealth at the forefront of international healthcare innovation and service provision. Building upon this significant momentum, PureHealth is advancing its expansion strategy in 2024. This strategic vision includes not only acquisitions in locally, but also international markets building a global healthcare platform. As PureHealth moves forward with its strategic global expansion, it remains committed to its mission of delivering unrivalled healthcare experiences through innovation, technology-driven solutions, and collaboration. This transaction not only enhances PureHealth's services and presence in the international healthcare landscape but also solidifies the company’s position as a leader in the healthcare industry, dedicated to improving lives and fostering healthier communities worldwide, and taking PureHealth from Abu Dhabi to the World. About PureHealth By advancing the Science of Longevity, PureHealth is introducing the healthcare of the future from the United Arab Emirates to the rest of the world. PureHealth is the largest healthcare platform in the Middle East with an ecosystem that challenges lifespans and reimagines health spans. With 25+ hospitals, 100+ clinics, multiple diagnostic centres, health insurance solutions, pharmacies, health tech, procurement, investments and more. With groundbreaking innovations at the forefront of healthcare, the company is on a mission to unlock time for humankind.

Read More

Medical Devices

Medtronic Diabetes announces world's first approval for MiniMed™ 780G System with Simplera Sync™ disposable, all-in-one sensor

Medtronic | January 08, 2024

Medtronic plc a global leader in healthcare technology, today announced CE (Conformité Européenne) Mark approval for the MiniMed™ 780G system with Simplera Sync™, a disposable, all-in-one continuous glucose monitor (CGM) requiring no fingersticks or overtape. Simplera Sync™ features an improved user experience with a simple, two-step insertion process and is half the size of previous Medtronic sensors. The MiniMed 780G system with Simplera Sync™ sensor will be available in Europe via limited release in spring 2024. Medtronic will begin the phased commercial launch in Europe in the summer of 2024. Today, the MiniMed™ 780G system can be used with the Guardian™ 4 sensor. The MiniMed™ 780G system is Medtronic's most advanced insulin delivery system, automatically adjusting and correcting† glucose levels every 5 minutes.§ It's the world's only system with a Meal Detection™ feature‡ that is designed to reduce post-meal hyperglycemia when users occasionally forget to give themselves insulin or underestimate the number of carbs in their snacks or meal. The system, which is available with the world's only 7-day infusion set, also features one of the lowest glucose target settings (as low as 100 mg/dL) of any automated insulin delivery system. With this "treat to target" approach, the system more closely mirrors the glucose levels of someone not living with diabetes. With both Simplera Sync™ sensor and the Guardian™ 4 sensor, no fingersticks are required. "A challenging aspect of living with diabetes is counting carbohydrates and dosing the right amount of insulin before consuming snacks and meals. Many people underestimate their carbs, which can lead to high blood sugars (hyperglycemia). Prolonged hyperglycemia can lead to serious health problems impacting the eyes, major organs, and even cognitive function, which is particularly concerning in developing children," Robert Vigersky, M.D., Chief Medical Officer, Medtronic Diabetes, Professor of Medicine, Uniformed Services University of the Health Sciences "With its responsive algorithm, the MiniMed™ 780G system can help people living with diabetes even when they occasionally forget to bolus or undercount their carbs. The system takes on more of the work involved in diabetes management and helps alleviate mental burden." "We're incredibly proud that the MiniMed™ 780G system continues to be the most widely used automated insulin delivery system in Europe since we launched it in 2020. Real-world data on over 100,000 users on the system across many geographies and cultures shows that when using recommended settings the system is delivering an average Time in Range of nearly 80%, raising the bar on what 'good' looks like2," said Que Dallara, EVP and President, Medtronic Diabetes. "With the introduction of Simplera Sync™ sensor, we're able to offer the proven benefits of our MiniMed™ 780G system with our newest and most comfortable sensor that can be applied in under 10 seconds." The MiniMed™ 780G system with Simplera Sync™ sensor is indicated for ages 7+ and compatible with iOS and Android. Simplera Sync™ sensor is not approved by the FDA and is limited to investigational use in the U.S. Simplera Sync™ sensor is designed to leverage Medtronic's advanced AID algorithm as part of its MiniMed™ 780G system while having a similar look and feel as the Simplera™ CGM. The Simplera™ CGM for integrated use with the InPen™ smart insulin pen received CE Mark in September 2023. About the Diabetes Business at Medtronic Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

Read More